Granisetron Transdermal Patch and Erythromycin: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Erythromycin
Granisetron Transdermal Patch
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased risk of QT interval prolongation
Interaction Deep Dive
Coadministration of erythromycin with other QT interval prolonging agents it may cause additive effects on the QT interval prolongation123.
Why it happens (mechanism)
Additive QT interval prolongation
Literature reports
2 reports — tap to read
a) Erythromycin significantly increased the QTc interval compared with baseline in a retrospective study of 49 patients. The erythromycin dose was 500 milligrams or 1 gram four times daily, with a mean of 15 doses received. Patients (n equal to 9) who received 60 mg/kg/day or more all developed increases in QT interval of 15% or greater. For all patients, the mean QTc interval increased from 432 milliseconds (msec) at baseline to 483 msec (p less than 0.01). In patients with delayed repolarization at baseline (n equal to 9), the QTc interval increased from 473 msec to 525 msec (p less than 0.01). In patients with heart disease (n equal to 30), all experienced an increase in QTc interval (mean of 15%), compared with an increase of 8% in patients without heart disease (p less than 0.05). In 5 patients (10%), the QTc interval was severely prolonged. One patient developed torsades de pointes attributed to erythromycin. Of 16 patients receiving cotrimoxazole concomitantly, 8 developed QT prolongation of 15% or greater 4.
b) Erythromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fatalities have been reported 123.
Common questions
Can I take Granisetron Transdermal Patch and Erythromycin together?
Increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Granisetron Transdermal Patch and Erythromycin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Granisetron Transdermal Patch or Erythromycin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: Erythromycin Lactobionate IV injection lyophilized powder for solution, erythromycin lactobionate IV injection lyophilized powder for solution. Nexus Pharmaceuticals (per DailyMed), Lincolnshire, IL, 2024.
- Product Information: Erythromycin oral delayed-release capsules, erythromycin oral delayed-release capsules. Dr. Reddy's Laboratories Inc. (per DailyMed), Princeton, NJ, 2025. DailyMed
- Product Information: ERYTHROMYCIN ETHYLSUCCINATE oral suspension granule, erythromycin ethylsuccinate oral suspension granule. ANI Pharmaceuticals, Inc (per DailyMed), Baudette, MN, 2025. DailyMed
- Oberg KC & Bauman JL: QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995; 15(6):687-692. DOI
Keep reading about Erythromycin
Keep reading about Granisetron Transdermal Patch
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist